IF 2014

Published: 2015-08-31

Selective Ability of Some CANTAB Battery Test Measures to Detect Cognitive Response to a Single Dose of Donepezil in Alzheimer Disease

Jurgita Kuzmickienė, Gintaras Kaubrys

(Clinic of Neurology and Neurosurgery, Faculty of Medicine, Vilnius University, Vilnius, Lithuania)

Med Sci Monit 2015; 21:2572-2582

DOI: 10.12659/MSM.895381

BACKGROUND: The Cambridge Neuropsychological Test Automated Battery (CANTAB) was used to explore which tests and their measures are able to detect cognitive change after a single dose of donepezil in Alzheimer disease (AD) patients. The aim of this study was to establish the ability of CANTAB tests and their measures to detect cognitive change after a single 5-mg dose of donepezil in treatment-naïve AD patients.
MATERIAL AND METHODS: We enrolled 62 treatment-naïve AD patients and 30 healthy controls in this prospective, randomized, rater-blinded study. AD patients were randomized to 2 groups: the AD+ group received donepezil after the first CANTAB testing and the AD– group remained treatment-naïve at second testing. The time period between repeated testing was 4 hours. Parallel versions of CRT, SOC, PAL, SWM, and PRM tests were used.
RESULTS: All groups did not differ according to age, education, gender, or depression (p>0.05). AD+ and AD– groups did not differ according to MMSE. SOC, PAL, PRM, and SWM tests distinguished AD from controls. Eight measures of PAL and PRM had a strong correlation with MMSE (r>0.7). Repeated-measures ANOVA with Bonferroni post-hoc test showed the difference of change in AD+ and AD– groups between first and second CANTAB testing in 7 PAL measures. AD+ and AD– groups differed in the second testing by 7 PAL measures. Four PAL measures differed in first and second testing within the AD+ group.
CONCLUSIONS: The CANTAB PAL test measures, able to detect cognitive change after a single dose of donepezil in AD patients, are: PAL mean trials to success, total errors (adjusted), total errors (6 shapes,... read more

Keywords: Alzheimer Disease, Cholinesterase Inhibitors, Dementia, Neurobehavioral Manifestations, Paired-Associate Learning, Treatment Outcome

Published: 2015-08-30

PTPN22 R620W Polymorphism is Associated with Myasthenia Gravis Risk: A Systematic Review and Meta-Analysi...

Xunbo Xiong, Mingqing Xiang, Xianglin Cheng, Yi Huang

Med Sci Monit 2015; 21:2567-2571

DOI: 10.12659/MSM.894307

Published: 2015-08-29

Identification of Aberrant Chromosomal Regions in Human Breast Cancer Using Gene Expression Data and Rela...

Hong-Jiu Wang, Meng Zhou, Li Jia, Jie Sun, Hong-Bo Shi, Shu-Lin Liu, Zhen-Zhen Wang

Med Sci Monit 2015; 21:2557-2566

DOI: 10.12659/MSM.894887